
Congress trades
Jazz Pharmaceuticals plc (JAZZ)
NASDAQ · Healthcare · 13 congress trades · last filed 3 years ago
About Jazz Pharmaceuticals plc
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Renee D. Gala
- Employees
- 2,890
- Listed since
- Jun 1, 2007
- Market value
- $15.2B
- Price to earnings
- 15.9
- Earnings per share
- $14.89
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 4, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 3, 2026 | $5.71 | $6.18 | $1.2B | $1.1B | EPS missRevenue beat |
| Q1 FY2026reported May 5, 2026 | $6.34 | $4.64 | $1.1B | $978.7M | EPS beatRevenue beat |
| Q4 FY2025reported Feb 24, 2026 | $6.64 | $6.52 | $1.2B | $1.2B | EPS beatRevenue beat |
| Q3 FY2025reported Nov 5, 2025 | $8.13 | $5.95 | $1.1B | $1.1B | EPS beatRevenue in line |
| Q2 FY2025reported Aug 5, 2025 | -$8.25 | -$6.12 | $1.0B | $1.0B | EPS missRevenue in line |
| Q1 FY2025reported May 6, 2025 | $1.68 | $4.51 | $897.8M | $1.1B | EPS missRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Jun 8, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Renee D. GalaPresident, CEO and Director | $1.0M | $16.1M | $2.0M | $19.2M |
| Robert Iannone, M.D., M.S.C.EExecutive Vice President, Global Head of R&D | $793K | $7.0M | $865K | $8.7M |
| Philip L. JohnsonExecutive Vice President and CFO | $741K | $6.0M | $756K | $7.5M |
| Neena M. PatilExecutive Vice President and Chief Legal Officer | $715K | $4.8M | $740K | $6.3M |
| Samantha PearceExecutive Vice President, Chief Commercial Officer | $696K | $4.7M | $721K | $6.1M |
The summary compensation table from the 2025 proxy statement, current executives only. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Blackrock, Inc. | $1.4B | 5,968,603 | +6.7% | 9.44% |
| FMR LLC | $1.1B | 4,609,326 | +102.5% | 7.29% |
| Vanguard Portfolio Management LLC | $731.6M | 3,036,213 | +1.8% | 4.80% |
| Vanguard Capital Management LLC | $657.8M | 2,729,650 | +3.1% | 4.32% |
| Capital World Investors | $650.0M | 2,697,610 | +0.9% | 4.27% |
| LSV Asset Management | $548.2M | 2,275,145 | -4.7% | 3.60% |
| Franklin Resources Inc | $491.6M | 2,040,250 | +4.2% | 3.23% |
| State Street Corp | $481.9M | 1,999,816 | +5.7% | 3.16% |
| Dimensional Fund Advisors LP | $412.9M | 1,713,592 | -9.6% | 2.71% |
| Fuller & Thaler Asset Management, Inc. | $394.8M | 1,638,544 | -2.2% | 2.59% |
| Bank Of New York Mellon Corp | $380.3M | 1,578,013 | -6.0% | 2.50% |
| AQR Capital Management LLC | $359.9M | 1,522,568 | +13.8% | 2.41% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
Congress trades in JAZZ
13 disclosures of 13 on record · median 24d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Daniel S. Goldman | Stock | Sale | $15,001 - $50,000 | +92.6%S&P +71.0% · vs S&P 500 +21.5% | Jul 12, 2023 | Aug 13, 2023 | 32d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +78.8%S&P +83.1% · vs S&P 500 -4.3% | May 19, 2023 | Jun 12, 2023 | 24d |
| Daniel S. Goldman | Stock | Purchase | $15,001 - $50,000 | +69.0%S&P +88.5% · vs S&P 500 -19.5% | Mar 6, 2023 | Apr 17, 2023 | 42d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +77.5%S&P +95.6% · vs S&P 500 -18.1% | Mar 14, 2023 | Apr 7, 2023 | 24d |
| Daniel S. Goldman | Stock | Sale | $1,001 - $15,000 | +54.0%S&P +87.7% · vs S&P 500 -33.6% | Jan 31, 2023 | Feb 24, 2023 | 24d |
| Thomas R. Suozzi | Stock | Sale | $1,001 - $15,000 | +87.9%S&P +108.7% · vs S&P 500 -20.9% | Sep 26, 2022 | Oct 14, 2022 | 18d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +91.6%S&P +65.9% · vs S&P 500 +25.7% | Dec 17, 2021 | Jan 7, 2022 | 21d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +81.9%S&P +63.8% · vs S&P 500 +18.0% | Nov 9, 2021 | Dec 7, 2021 | 28d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +77.6%S&P +65.8% · vs S&P 500 +11.8% | Nov 2, 2021 | Dec 7, 2021 | 35d |
| Thomas R. Suozzi | Stock | Purchase | $1,001 - $15,000 | +66.0%S&P +69.4% · vs S&P 500 -3.4% | Oct 19, 2021 | Nov 5, 2021 | 17d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +72.7%S&P +201.0% · vs S&P 500 -128.3% | Dec 17, 2018 | Jan 11, 2019 | 25d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +74.0%S&P +184.1% · vs S&P 500 -110.1% | Jan 2, 2018 | Feb 11, 2018 | 40d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +71.1%S&P +188.5% · vs S&P 500 -117.4% | Nov 30, 2017 | Dec 12, 2017 | 12d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Members of Congress reporting a position
1 member · estimate, as of Sep 10, 20261 member reports a position (estimated). The largest estimated position is in the $50,001 - $100,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Jacky Rosen | Democrat · Senate | $50,001 - $100,000 | 1.0% |
Estimate, as of Sep 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Which members of Congress have traded JAZZ?
Daniel S. Goldman, Ro Khanna, Thomas R. Suozzi disclosed JAZZ transactions in the filings shown here.
Which members of Congress hold JAZZ?
1 member of Congress reports a position in JAZZ in the estimate we hold as of Sep 10, 2026. The largest estimated position belongs to Jacky Rosen. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
How quickly are JAZZ trades disclosed?
Congressional disclosures took a median of 24 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.
